Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Niagen Bioscience IncNASDAQ: NAGE

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $1.72M rose 59.6% year over year, behind the +79.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Stock-based compensation amounted to 4.7% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +59.6% toward the trailing-twelve-month pace of +79.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.72M-1.8% QoQ
Last fiscal yearDec 2025
$6.07M+65.9% YoY
LTMMar 2026
$6.71M+79.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.6%——
1 year+65.9%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
6.07M USD
Year-over-year change
+65.9%
4-year CAGR
-0.5%

Stock-Based Compensation vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 stock-based compensation of $6.71M is the 9th largest of the 10 companies compared; the peer median is $12.84M.
  • Its year-over-year change of +79.0% is the 2nd highest of 9, against a peer median of -14.0%.
  • Stock-based compensation amounts to 5.1% of revenue for NAGE, versus a peer median of 10.3%.
NAGE Competitors Peer median
Stock-Based Compensation for NAGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
PRTAProthena Corporation plcLTM Mar 2026$33.61M -24.5%+6.3%58.0%
KROSKeros Therapeutics, Inc.LTM Mar 2026$26.03M -27.0%+15.4%78.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M -40.1%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M +67.9%-14.2%5.5%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$12.62M -20.6%+43.3%10.3%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M +88.8%+25.6%—
NAGENiagen Bioscience IncLTM Mar 2026$6.71M +79.0%+1.9%5.1%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$5.38M ——4.6%
Peer median (excluding NAGE) $12.84M-14.0%+6.3%10.3%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
Deferred Income Tax00000
Stock-Based Compensation6.2M5.74M4.75M3.66M6.07M
Change in Working Capital(4.73M)(6.01M)4.62M3.13M(8.3M)
Accounts Receivables(2.58M)(3.32M)2.26M(1.28M)(756K)
Inventory(1.92M)(1.08M)152K5.33M(11.64M)
Accounts Payables978K(744K)553K(1.07M)2.27M
Other Working Capital(1.21M)(875K)1.66M147K1.83M
Other Non-Cash Items(124K)(167K)977K(4.72M)(3.17M)
Operating Cash Flow(24.16M)(15.1M)7.12M12.11M13.44M
Capital Expenditures(409K)(334K)(148K)(163K)(292K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities005K20K0
Investing Cash Flow(409K)(334K)(143K)(143K)(292K)
Debt Repayment(31K)(16K)(15K)(11K)(12K)
Common Stock Issued26.74M7.75M05.43M7.25M
Common Stock Repurchased0000(251K)
Dividends Paid00000
Other Financing Activities9.39M(77K)(75K)(52K)0
Financing Cash Flow36.09M7.65M(90K)5.37M6.98M
Effect of Forex Changes00000
Net Change in Cash11.52M(7.78M)6.88M17.34M20.13M
Free Cash Flow(24.57M)(15.43M)6.97M11.95M13.15M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.